Graft Versus Host Disease

• Graft Versus Host Disease (GVHD) is an immune reaction where donor cells attack recipient tissues after a transplant.
• It primarily occurs after allogeneic stem cell or bone marrow transplants.
• Symptoms vary depending on whether it’s acute or chronic GVHD, affecting organs like the skin, liver, and gastrointestinal tract.
• The condition arises because the donor’s immune system perceives the recipient’s cells as foreign.
• Treatment often involves immunosuppressive medications to manage the immune response and alleviate symptoms.

What is Graft Versus Host Disease?

Graft Versus Host Disease (GVHD) is a complex immunological reaction that can arise following an allogeneic hematopoietic stem cell transplant (HSCT). In this procedure, a patient receives healthy blood-forming stem cells from a donor to replace their own diseased or damaged cells. While the primary goal is to reconstitute the patient’s immune system and treat underlying conditions like leukemia or lymphoma, a critical risk is that the donor’s immune cells (the “graft”) may identify the recipient’s tissues (the “host”) as foreign and launch an immune attack against them. This immune response can affect various organs throughout the body.

GVHD is broadly categorized into two main forms: acute and chronic. Acute GVHD typically develops within the first 100 days post-transplant, often manifesting suddenly and severely. Chronic GVHD, on the other hand, can emerge later, sometimes months or even years after the transplant, and tends to have a more persistent and widespread impact, resembling autoimmune diseases. The severity of both forms can range from mild to life-threatening, making it a significant challenge in transplant medicine.

Causes and Symptoms of Graft Versus Host Disease

The primary causes of Graft Versus Host Disease stem from the immunological incompatibility between the donor’s immune cells and the recipient’s tissues. Even with a close match, minor differences in human leukocyte antigens (HLAs) can trigger the donor’s T-cells to recognize the recipient’s cells as foreign. These activated T-cells then initiate an inflammatory response, leading to tissue damage in various organs. The risk of developing GVHD is influenced by several factors, including the degree of HLA mismatch, the donor source (e.g., related vs. unrelated), the intensity of the conditioning regimen before transplant, and the patient’s age and overall health.

The graft versus host disease symptoms are diverse and depend heavily on whether the condition is acute or chronic, as well as which organs are affected. Acute GVHD commonly targets rapidly dividing cells in specific organs, while chronic GVHD can affect almost any organ system, often mimicking autoimmune disorders. Common symptoms include:

• Skin: Rashes, redness, itching, blistering, and skin tightening (scleroderma-like changes in chronic GVHD).
• Gastrointestinal Tract: Nausea, vomiting, diarrhea (often watery or bloody), abdominal pain, and loss of appetite.
• Liver: Jaundice (yellowing of the skin and eyes), elevated liver enzymes, and liver dysfunction.
• Mouth: Dryness, pain, sensitivity to food, mouth sores, and difficulty swallowing (in chronic GVHD).
• Eyes: Dryness, irritation, light sensitivity, and vision changes (in chronic GVHD).
• Lungs: Shortness of breath, persistent cough, and recurrent infections (in chronic GVHD).
• Musculoskeletal System: Joint pain, stiffness, and muscle weakness (in chronic GVHD).

Early recognition of these symptoms is crucial for timely intervention and better management of the disease, as untreated GVHD can lead to severe organ damage and increased mortality.

Graft Versus Host Disease Treatment Options

Managing graft versus host disease treatment involves a multi-faceted approach aimed at suppressing the donor’s immune response while minimizing side effects and preserving the beneficial anti-tumor effect of the graft. The cornerstone of treatment for both acute and chronic GVHD is typically immunosuppressive medication.

Corticosteroids, such as prednisone or methylprednisolone, are the most common first-line therapy due to their potent anti-inflammatory and immunosuppressive properties. They work by reducing the activity of the donor T-cells that are attacking the host tissues. However, long-term use of corticosteroids can lead to significant side effects, including increased risk of infection, bone density loss, and metabolic disturbances.

For patients who do not respond adequately to corticosteroids or who experience severe side effects, second-line therapies may be considered. These can include other immunosuppressants like calcineurin inhibitors (e.g., tacrolimus, cyclosporine), mTOR inhibitors (e.g., sirolimus), or monoclonal antibodies (e.g., rituximab, ruxolitinib). Ruxolitinib, for instance, has shown efficacy in treating steroid-refractory acute and chronic GVHD by targeting specific signaling pathways involved in immune cell activation. Source: National Cancer Institute (NCI).

Beyond medication, supportive care is vital. This includes managing pain, providing nutritional support, preventing infections, and addressing specific organ damage. For example, photopheresis, a procedure that treats a patient’s white blood cells with UV light and a photosensitizing agent before returning them to the body, is another option for chronic GVHD affecting the skin. Prevention strategies, such as careful donor matching and prophylactic immunosuppression immediately after transplant, are also critical in reducing the incidence and severity of GVHD.